Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer
Abiraterone acetate plus prednisolone added to ADT + docetaxel, gives 25% reduction in risk of death compared to ADT + docetaxel alone in prostate cancer
Impact of cytogenetic abnormalities on treatment outcomes in patients with AL amyloidosis
Impact of biomarkers on pCR and survival after T-DM1 with or without ET vs trastuzumab and ET in HER2/HR positive early BC
Immunotherapy prolongs survival in recurrent, persistent or metastatic cervical cancer
6 months trastuzumab non-inferior to 12 months for HER2 positive early breast cancer
Multidisciplinary management of ovarian germ cell tumours - a single institutional study from India
Suboptimal humoral immune response to COVID-19 vaccination in myeloma patients
Clinical outcomes of relapsed/refractory multiple myeloma patients after BCMA-targeted CAR T therapy
Retrospective analysis of COVID-19 infection in 371 Czech multiple myeloma patients
OncoAlert and ecancer weekly round up for August 23rd - August 29th, 2021
OncoAlert and ecancer weekly round up for August 16th - August 22nd, 2021
OncoAlert and ecancer weekly round up for July 26 - August 1, 2021